|
|
|
| Clinical effect of Terbutaline combined with Ipratropium Bromide in the treatment of chronic obstructive pulmonary disease |
| XU Jing-yi WEN Xian FENG Hai-xuan |
| Department of Respiratory Medicine,Shenzhen Luohu District People′s Hospital,Guangdong Province,Shenzhen 518000,China |
|
|
|
|
Abstract Objective To investigate the clinical effect of terbutaline combined with Ipratropium Bromide in the treatment of chronic obstructive pulmonary disease (COPD).Methods A total of 153 patients with COPD admitted to our hospital from January 1,2017 to December 31,2018 were enrolled in this study.They were divided into reference group (75 cases) and observation group (78 cases) according to the parity grouping method.The reference group was treated with Terbutaline,the observation group was treated with Terbutaline combined with Ipratropium Bromide.The blood gas index,lung function index and clinical efficacy of the two groups of patients were analyzed and compared.Results After treatment,the levels of arterial oxygon sataration (SaO2) and arterial partial pressure of oxgyon (PaO2) in the observation group were higher than those in the reference group,and the level of arterial pantial pressure of carbon dvoxide (PaCO2) was lower than that in the reference group,the differences were statistically significant (P<0.05).The forced expiratory volume in the first second (FEV1),forced vital capacity (FEV1/FVC) and peak expiratony flow (PEF)levels in the observation group were higher than those in the reference group,the differences were statistically significant (P<0.05).The total effective rate of the observation group was 83.33% (65/78),which was higher than that of the reference group (50.67%),and the difference was statistically significant (P<0.05).Conclusion The clinical effect of Terbutaline combined with Ipratropium Bromide in the treatment of COPD is better,which can improve the blood gas index and lung function index of patients,and play a positive role in the stability of the disease.
|
|
|
|
|
|
| [1] |
吴丹，吕志，黄勇，等.布地奈德福莫特罗治疗慢阻肺稳定期与慢阻肺合并肺癌稳定期患者的疗效比较[J].临床肺科杂志，2017，22（3）：534-537.
|
| [2] |
左声勇.糖皮质激素联合特布他林治疗慢阻肺急性加重期40例用药效果初评[J].中外医学研究，2016，14（9）：133-134.
|
| [3] |
戢太兵，艾红艳，秦永刚，等.哮喘-慢阻肺重叠综合征采用沙美特罗氟替卡松分别联合噻托溴铵和复方异丙托溴铵治疗的效果对比[J].中外医学研究，2019，17（6）：32-33.
|
| [4] |
徐月清，王晓玲.噻托溴铵联合沙美特罗氟替卡松应用于慢阻肺治疗中的疗效分析[J].中国保健营养，2016，26（7）：346.
|
| [5] |
王宏俊.长效支气管舒张剂在慢性阻塞性肺疾病稳定期治疗中的应用进展[J].临床肺科杂志，2017，22（7）：1326-1330.
|
| [6] |
刘美璇，张倩，黄建浩，等.白三烯受体拮抗剂（LTRA）对哮喘-慢阻肺重叠（ACO）患者气道炎症的影响及相关机制[J].复旦学报（医学版），2018，45（6）：852-857.
|
| [7] |
张华根，曾伟坚，彭贵霞，等.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在哮喘-慢阻肺重叠综合征患者治疗中的应用研究[J].实用药物与临床，2018，21（7）：811-814.
|
| [8] |
张健，李兰，范世明，等.无创双水平正压通气与呼吸兴奋剂辅助治疗慢阻肺急性呼吸衰竭的临床探究[J].中国急救医学，2017，37（Z1）：197-198.
|
| [9] |
张宏，孙辉，欧阳文，等.不同时机行有创机械通气治疗慢阻肺急性发作合并重度呼吸衰竭患者的对照研究[J].中国煤炭工业医学杂志，2017，20（2）：139-144.
|
| [10] |
吉泽，潘星，姬峰，等.呼出气一氧化氮检测在哮喘-慢阻肺重叠综合征治疗中的应用价值[J].第二军医大学学报，2016，37（10）：1250-1255.
|
| [11] |
卓致远，武焱旻，张琦，等.噻托溴胺联合呼吸操训练治疗稳定期慢性阻塞性肺病患者的临床研究[J].临床肺科杂志，2016，21（12）：2287-2290，2305.
|
| [12] |
胡天洋，蒋幼凡.糠酸氟替卡松/芜地溴铵/维兰特罗三联吸入治疗慢性阻塞性肺疾病的研究进展[J].临床肺科杂志，2017，22（11）：2095-2098.
|
| [13] |
戴志辉，冯长溪，骆莹莹，等.天晴速乐联合舒利迭治疗支气管哮喘-慢阻肺重叠综合征的可行性研究[J].中国生化药物杂志，2017，37（8）：329-330.
|
| [14] |
祁云霞，吴美萍，邓顺娟，等.二陈汤合三子养亲汤治疗慢阻肺急性加重期疗效观察[J].世界中医药，2016，11（11）：2278-2280，2285.
|
| [15] |
刘雪琴，关晓暄，孙立军，等.噻托溴铵联合沙美特罗/氟替卡松治疗哮喘——慢阻肺重叠综合征的临床评价[J].临床肺科杂志，2017，22（3）：513-516.
|
| [16] |
陈石，李磊，吴刚，等.吸入激素联合噻托溴铵治疗哮喘-慢阻肺重叠综合症的临床疗效评价[J].临床肺科杂志，2015，20（10）：1856-1860.
|
| [17] |
倪敏讷，童朝晖.噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢阻肺重叠综合征122例[J].中国生化药物杂志，2017，37（8）：206-207.
|
| [18] |
唐甦.支气管舒张剂联合抗胆碱药治疗慢阻肺的临床效果分析[J].陕西医学杂志，2017，46（4）：490-491.
|
|
|
|
